|
Feb 28
|
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
|
|
Jan 11
|
With 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interest
|
|
Dec 1
|
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
|
|
Dec 1
|
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Price Is Right But Growth Is Lacking After Shares Rocket 27%
|
|
Nov 7
|
News Flash: Analysts Just Made A Sizeable Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts
|
|
Nov 3
|
Foghorn Therapeutics Inc (FHTX) Reports Q3 2023 Financial Results and Corporate Updates
|
|
Nov 2
|
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
|
|
Aug 8
|
Foghorn Therapeutics Announces Chief Medical Officer Succession
|
|
Aug 4
|
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 4
|
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
|
|
Apr 27
|
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
|
|
Apr 25
|
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
|
|
Apr 24
|
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
|
|
Apr 24
|
UPDATE 1-Foghorn Therapeutics pauses enrollment in cancer drug study
|
|
Apr 24
|
Foghorn Therapeutics Provides an Update on FHD-609
|